
    
      This is a phase I, single center, randomized, double-blind and parallel group clinical trial
      .

      The primary objective is to assess the pharmacokinetic similarity of single subcutaneously
      injection of HS-20090 or Xgeva® in healthy volunteers.

      The secondary objectives are to assess the Clinical safety and immunogenicity similarity of
      single subcutaneously injection of HS-20090 or Xgeva® in healthy volunteers.
      Meanwhile，observing the pharmacodynamic similarity of HS-20090 to Xgeva® preliminarily.
    
  